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Abstract 
Tuberculosis is the leading cause of death from infectious disease in the world. Although 
tuberculosis drugs exist, the rise of drug-resistant tuberculosis has created a need for new 
research. Identifying novel, effective drugs for treatment of tuberculosis could reduce the 
cost of care and treatment time, saving millions of lives. The enzyme KasA, which 
synthesizes part of the tuberculosis bacterial cell wall, has been identified as an attractive 
drug target. A virtual screen using KasA discovered a compound, 4-(4-bromophenyl)-1-
pyrenemethyl-4-piperidinol (1), which inhibited bacterial growth in vitro. In this 
research, nine derivatives of compound 1 were synthesized for future testing with live 
bacteria. A lithium-halogen exchange reaction was used to attempt to create a 
piperidinone-based derivative with varied substituents, but the method yields were low 
and difficult to purify. A Grignard process was also attempted with similar results. 
Alkylation of 4-substituted-4-piperidinols was successful in creating derivatives with 
arylmethyl substituents in yields from 51-85%. A silane reduction to remove the 4-
hydroxy group was also explored but exhibited low yields. In future research, these 
derivatives will be tested in vitro to determine suitability for development as potential 
tuberculosis drugs. 
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I. Introduction 
Tuberculosis (TB) is the worldwide leading cause of death from infectious 
disease. In 2016, there were six million new cases of TB, and although the death rate has 
decreased by an average of 3% per year since 2000, 16% of cases still result in death.1 In 
the same year, multi-drug resistant tuberculosis (MDR-TB), resistant to front-line drugs 
such as rifampin and isoniazid,2 was discovered in 490,000 cases.1 Treatment success for 
MDR-TB is just 54%, and the need for novel chemotherapeutics is rising.1 
TB is a disease of the lungs caused by Mycobacterium tuberculosis, a member of  
a family of bacteria characterized by thick, waxy cell walls. These cell walls are made up 
of numerous long-chain fatty acids called mycolic acid, shown in Figure 1.3 Their 
structure consists of two branches: the longer meromycolate chain and a shorter saturated 
chain. The fatty acid synthase II (FAS II) group of enzymes is responsible for the 
metabolic pathway generating the meromycolate chain, shown in Figure 2A. Multiple 
FAS II enzymes have been targeted for development as drugs for the treatment of MDR-
TB.2 
OH
OH
O
O
 
Figure 1: A mycolic acid, a characteristic long fatty acid that makes up part of the cell 
wall of m. tuberculosis. As part of the FAS II condensing system, KasA is responsible for 
the elongation of the top chain, called the meromycolate backbone. 
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Figure 2: A. A diagram of the FAS II metabolic pathway, with KasA and its 
substrate boxed. The R1 group is the lengthening meromycolate chain.
4 B. A detail of the 
reaction catalyzed by KasA, where AcpM is an acyl group carrier protein that shuttles 
growing chains throughout the FAS II system. KasA lengthens the meromycolate chain 
by one carbon on each catalytic cycle. 
 
The FAS II pathway consists of enzymes which form and elongate the long-
chained fatty acid, a critical contributor to the unique cell wall structure of 
mycobacteria.3,5 Inhibitors like isoniazid and triclosan have been developed for the FAS 
II enzyme InhA,6 and thiolactomycin and platensimycin target KasA and KasB.7–9 KasA, 
also called β-ketoacyl-acyl carrier protein synthase I, is an attractive drug target because 
its inhibition leads to bacterial cell death.10 
The KasA enzyme is responsible for catalyzing a Claisen condensation that 
creates a β-keto ester, the result of a carbon-carbon bond between an ester and carbonyl, 
shown in Figure 2B.4 This reaction is necessary for the early growth of the long chain 
fatty acids which become mycolic acid.11 The structure of KasA, shown in Figure3, is 
homodimeric, made of two symmetrical lobes which can partially open in a scissoring 
A 
B 
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motion to accommodate long hydrophobic chains, funneling the substrate to the active 
site near the center of the enzyme.12 
  
Figure 3: The crystal structure and enzyme opening proposed by Luckner et al. shows 
the two lobes of KasA in gray and blue, and the flexible opening of the enzyme in orange 
and red ribbons. Shown in red and yellow spheres are polyethylene glycol chains filling 
the hydrophobic acyl channels.12 
 
With the advent of powerful bioinformatic tools, new drugs can be discovered via 
virtual enzyme-ligand modeling13, and many new potential drug targets have been 
discovered by virtual screen.14,15 An effective competitive inhibitor of KasA would 
prevent the enzyme from binding its typical substrate. This would prevent the elongation 
of the meromycolate backbone and the formation of the critical mycolic fatty acids that 
make up the mycobacterial cell wall, killing the bacteria. A KasA inhibitor could become 
a potential drug for treatment of MDR-TB. 
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In previous work by this group, around four million unique compounds were 
modeled in the active site of KasA using AutoDock Vina. The compounds were tested for 
their dissociation constant (pKd) from the KasA active site, with the largest pKd 
indicating the greatest inhibitory effect. Of the compounds screened, six commercially 
available compounds were chosen due to their predicted pKd values, which ranged 
between 12.7 and 13.1. These high pKd indicate that very few inhibitor molecules would 
be dissociated from the enzyme at equilibrium. These were purchased and tested on 
Mycobacterium bovis, a nonpathogenic bacterium similar to M. tuberculosis. The results 
of this test are shown in Figure 4. The top three plates are a control and two compounds 
which had no effect on M. bovis. In the bottom three wells, 4-(4-bromophenyl)-1-
pyrenemethyl-4-piperidinol (1) is shown tested in concentrations of 50, 5, and 0.5 µM. Of 
the tested compounds, 1 was shown to inhibit bacterial growth at a concentration of 5 
µM, promising for future drug development. 
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Figure 4: The results of an in vitro test of the effect of three inhibitors on M. bovis 
growth. These inhibitors were predicted to have high pKd by virtual screen. The bottom 
left two wells, treated with compound 1 in concentrations of 50 and 5 μM, showed no 
bacterial growth. 
 
 Compound 1 is shown, along with the docking results proposed in the screen, in 
Figure 5. The docking results show the predicted way the inhibitor should bind to the 
enzyme. Compound 1 is displayed in gray, and the native substrate for the enzyme, acyl 
chains, are shown in blue and red. The bromoaryl ring of the inhibitor occupies the 
hydrophobic channel that would otherwise contain the alkyl chain of the acyl substrate, 
preventing its binding. The aromatic pyrenyl group fits in a pocket adjacent to the active 
site residues.  
50 μM 5 μM 0.5 μM 
1 
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Figure 5: The molecular structure of 1, a suspected inhibitor of KasA, along with its 
proposed docking configuration. Compound 1 is shown docked in gray, with the typical 
binding of the acyl chain substrate shown superimposed in blue and red. The bromoaryl 
ring occupies the same hydrophobic channel as the acyl chain substrate, preventing 
binding. 
 
The purpose of this work is to create a library of derivatives of the lead compound 
with varying substituents to be used in a structure-activity relationship study. Similar 
compounds to 1 may have greater affinity for the enzyme, may bind more easily, or may 
have different effects on other biological processes. They may also have no effect on the 
enzyme, as seen in the failed inhibitors in Figure 4, whose structures were similar to 
compound 1. To test the importance of each part of the structure, modifications can be 
made to the structure at position 1 and position 4 on the central piperidine ring. Positions 
which can be modified and the various alternative groups for each position are shown in 
Figure 6.  
By varying these substituents, the effect of each position on the inhibitor’s 
binding to KasA can be studied. The bromoaryl group at position 4 can be changed for a 
chlorophenyl, trifluoromethylphenyl, or phenyl group. These changes would test the 
1 
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significance of the bromine extending from the hydrophobic channel. The hydroxy group 
at position 4 can be exchanged for a hydrogen to observe if hydrogen bonding is 
significant to the inhibitor’s success. Finally, the large pyrene group at position 1 can be 
changed for smaller aryl groups like naphthylmethyl and benzyl, which may have 
different solubility properties and are less expensive to manufacture. Additionally, 
varying these groups to find different structures with similar inhibitory ability may 
provide viable alternatives with less toxicity to humans or other unwanted effects.  
 
Figure 6: Compound 1, is shown with each region targeted for modification hilighted. 
The bromophenyl group at position 4 shown highlighted in green with its replacement 
structures, chlorophenyl, trifluoromethylphenyl, and phenyl. The pyrenemethyl group is 
in blue at the 1 position of the piperdine backbone, with its replacements of phenylmethyl 
and naphthylmethyl. Finally, the hydroxy group targeted at position 4 is in orange, and is 
targeted for replacement with hydrogen. 
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 To investigate the significance of the structural components of compound 1, a 
collection of similar compounds will be synthesized with variations in position 1 and 4 on 
the piperidine backbone. In this work, two general approaches were used for the 
modification of the lead compound, outlined in Scheme 1. The alkylation-first approach 
follows the top line of the scheme. The 1 position of 2 is modified by alkylation to form 
4a-c, installing the desired aryl group. Next, a Grignard or alkyllithium reagent installs 
the aryl halide at position 4 of 4a-c. 
 The second line of the synthesis uses an alkylation-second approach. It reverses 
the order of modifications on the piperidine ring, modifying position 4 first, followed by 
position 1. In this approach 7 is converted to 8a-d is with a Grignard or alkyllithium 
reagent. The protecting group is removed with acid to form 9, and an alkylation is 
performed to install the aryl group to generate 1, 6a-k. 
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N
+
O
H HCl
–
R1 Cl
Na2CO3,
CH3CN
N
O
R1
M
( M = MgBr, Li)
2 4a-c
3a-c
5a-d
R1 Cl
Na2CO3
CH3CN
M
( M = MgBr, Li) N
Boc
OHR2
N
O
Boc
H
+
N
H
OHR2
N
R1
OH
7 8a-d 9a-d
5a-d
3a-c
R2
R2
R2
R
1
1:
6a:
R16b:
R16c:
R16d:
R16e:
R1 = pyrenyl  R2 = 4-Br
R1 = naphthyl R2 = 4-Br
R1 = phenyl R2 = 4-Br
R1 = phenyl R2 = 4-Cl
R1 = naphthyl R2 = 4-Cl
R1 = pyrenyl R2 = 4-Cl
R
13
3a, 4a:
R13b, 4b:
R1443c, 4c:
R1 = phenyl
R1 = naphthyl
R1 = pyrenyl
R
1
5a, 8a, 9a:
R15b, 8b, 9b:
R15c, 8c, 9c:
R15d, 8d, 9c:
R2 = 4-Br
R2 = 4-Cl
R2 = 3-CHF3
R2 = H
1, 6a-k
R16f:
R16g:
R16h:
R16i:
R16j:
R16k:
R1 = phenyl R2 = 3-CHF3
R1 = naphthyl R2 = 4-CHF3
R1 = pyrenyl R2 = 4-CHF3
R1 = phenyl  R2 = H
R1 = naphthyl R2 = H
R1 = pyrenyl R2 = H   
Scheme 1: Two possible approaches to synthesis of derivatives of compound 1 with 
modifications at the 1 and 4 positions.  
alkylation-first 
approach 
alkylation-
second 
approach 
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II. Results and Discussion 
Grignard and Lithiation Reactions with Piperidones 
  
N
O
R1
M
( M = MgBr, Li)
4a-c
5a-d
M
( M = MgBr, Li) N
Boc
OHR2
N
O
Boc
N
R1
OH
7 8a-d
5a-d
R2
R2
R2
1, 6a-k
R
1
5a, 8a:
R15b, 8b:
R15c, 8c:
R15d, 8d:
R2 = 4-Br
R2 = 4-Cl
R2 = 3-CHF3
R2 = H
R
13
3a, 4a:
R13b, 4b:
R1443c, 4c:
R1 = phenyl
R1 = naphthyl
R1 = pyrenyl
R
1
1:
6a:
R16b:
R16c:
R16d:
R16e:
R1 = pyrenyl  R2 = 4-Br
R1 = naphthyl R2 = 4-Br
R1 = phenyl R2 = 4-Br
R1 = phenyl R2 = 4-Cl
R1 = naphthyl R2 = 4-Cl
R1 = pyrenyl R2 = 4-Cl
R16f:
R16g:
R16h:
R16i:
R16j:
R16k:
R1 = phenyl R2 = 3-CHF3
R1 = naphthyl R2 = 4-CHF3
R1 = pyrenyl R2 = 4-CHF3
R1 = phenyl  R2 = H
R1 = naphthyl R2 = H
R1 = pyrenyl R2 = H  
Scheme 2: The two approaches to modification of the aryl group at the 4 position of the 
piperidine backbone. 
 
Both approaches outlined in Scheme 1 required a modification at the 4-position of 
the piperidine backbone, using either a Grignard reagent or an alkyllithium to add the 
desired R2 group at the carbonyl. These syntheses are shown in Scheme 2. The major 
difference between the two approaches is the presence of either the aryl group of the final 
intended product already installed in position 1, or a tert-butyloxycarbonyl (Boc) 
protecting group in this position to be removed later. These reactions were largely 
unsuccessful, and reaction monitoring by gas chromatography/mass spectrometry 
(GCMS) was used to attempt to discover why these reactions did not work as expected. 
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Grignard Reaction 
 
Scheme 3: Planned synthesis of the Grignard reagents. 
 
The Grignard approach was attempted for the creation of 6b from 4a. The first 
step of this reaction, the generation of the Grignard reagent 5a from 10a is outlined in 
Scheme 3. The reaction was carried out under dry conditions, and during reflux of 5a 
with magnesium, the magnesium did appear to be consumed. However, upon reaction a 
mixture of products was generated and large amounts of 5a were present. To test the 
formation of the Grignard reagent, the first step of the reaction (Scheme 3) was repeated 
and monitored by GCMS over 30-minute intervals during reflux. 
Samples of the reaction were quenched in water. Successful formation of the 
Grignard reagent could be monitored by the presence of the quenched product, 
bromobenzene. The chromatograms of the reaction of 10a showed large amounts of 
unreacted 10a during the initial 1.5 hours of reaction time, and after 24 hours of stirring 
little change was observed in the composition of the mixture. 
This monitoring process was repeated again with the addition of iodine as a 
catalyst for the reaction, but the result was the same, with 10a remaining largely 
unreacted. GC chromatograms (Figure 7) showed the relative growth of the 
bromobenzene signal after workup to a signal of equal strength to the starting material. 
Without knowing the relative response factor between the two substances, it is not 
12 
 
possible to draw significant conclusions about the extent to which this reaction went to 
completion, however greater conversion is desired. 
  
 
Figure 7: Four chromatograms from the reaction monitoring of the Grignard reaction of 
10a (1,4 dibromobenzene). The bromobenzene peak, indicating formation of product, has 
an equal peak area to the 10a peak at 70 minutes, and no improvement is seen after 70 
hours. 
 
 Using 10d, a monosubstituted bromobenzene, as a starting material to create a 
Grignard reagent to used for the conversion of 7 to 8d was met with more success. A GC 
chromatogram of the crude product of this reaction appeared relatively pure, with only 
one significant peak. The mass spectrum also supported the formation of the intended 
product. The M+ of the species in the chromatogram was 277, which is the expected mass 
of the intended product of this reaction. The spectrum and chromatogram are shown in 
Figure 8. 
 
8d 
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Figure 8: The chromatogram and mass spectrum of the product of a phenyl Grignard 
made from a mono-brominated benzene starting material with boc-piperidone. The mass 
of the molecular ion of the species in the mass spectrum is the same as the mass of the 
expected product. 
 
Overall, these results suggest that 10a may be a challenge for conversion into a 
Grignard reagent. This is an interesting result, as the literature suggests that 1,4-
dibromobenzene should react comparably to the monosubstituted aryl halide in 
tetrahydrofuran (THF) solvent.16 Possible development of this Grignard reaction could 
include testing a different dihalogenated starting material, like a bromoiodobenzene, in 
order to compare the performance of the reactions under similar conditions. 
Alternatively, a different exchange reagent from magnesium metal may have better 
results.17 This would allow greater insight into the effect of bromine disubstitution on this 
reaction. Also, quantitative monitoring of the reaction by GCMS would aid in 
understanding the success of the reaction. 
 
Lithiation Reaction 
 
 
 
Scheme 4: The lithium-halogen exchange using n-butyllithium. 
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The second approach to modification at the 4 position of the piperidine ring was 
to create a desired organolithium reagent to add an aryl group at the carbonyl by using a 
lithium-halogen exchange reaction. The first step of this process is outlined in Scheme 4. 
In this reaction, the carbanion of the n-BuLi reagent forms an ionic intermediate by 
attacking the halogen of 10a-d.18 This intermediate can then generate 5a’-d’ and 11. 
Although not used in further synthesis, 11 was used as a marker for successful lithium-
halogen exchange. 
Initial trials of this reaction followed Scheme 2, using 5a’ to add an aryl halide to 
4a. In one flask, the n-BuLi was added to 10a in -78°C tetrahydrofuran. The low 
temperature reduces the possibility of unwanted reactions with the solvent.19 After the 
dropwise addition of the n-BuLi, 4a was added. Workup of the reaction after adding 4a 
showed a mixture of products and remaining starting material in TLC. Because of this, 
the first step of the reaction, shown in Scheme 4, was repeated and monitored by GCMS 
to try to optimize the reaction. When initial trials showed large amounts of the unreacted 
10a starting material and no 11 present, the butyllithium was titrated with diphenylacetic 
acid to determine its concentration. As could be expected due to its high reactivity, the 
actual concentration of nBuLi reagent had decreased to half the original concentration.  
 
Br
Br Br
LinBuLi, THF
-78°C
O
Br
OH
 
 
Scheme 5: A model reaction was attempted using cyclohexanone instead of the more 
expensive piperidone. 
10a 5a’ 
12 
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In further testing, a model reaction was used with a cheaper alternative to 4a, 
cyclohexanone, as shown in Scheme 5. The reaction used an adjusted volume of nBuLi, 
and after the lithium-halogen exchange step, cyclohexanone (1 equiv) was added to the 
reaction mixture. Monitoring of the lithium halogen exchange reaction showed some 11 
formed, and no detectable 10a. After addition of cyclohexanone the reaction was worked 
up and characterized with GCMS. The labeled chromatogram in Figure 9 shows that 12 
was not formed, and many of the products were from unintended side reactions. 
Figure 9: A chromatogram of the reaction of 10a with n-BuLi, followed by 
cyclohexanone. Selected peaks are labeled to demonstrate the unwanted side reactions 
that occurred. 
 
 Although there was no unreacted 10a in the chromatogram, very little 
bromobutane, the marker for successful lithium-halogen exchange, was found. Side 
reactions with the n-BuLi itself are seen in peaks 2, 5, 6, and 7, including reactions with 
the solvent. 5a’ reacting with itself is seen in peaks 9 and 10. A large peak of unreacted 
cyclohexanone is in peak 3, and finally a compound similar to 12, but lacking bromine, is 
seen formed in peaks 8 and 11. Although quantitative information about the relative 
16 
 
concentrations of these side products, unreacted starting material, and desired products 
cannot be determined from the chromatogram, the overall selectivity of this reaction is 
certainly seen to be poor.   
 The reaction was further tested with various mixtures of product and unreacted 
starting material and substitution of 10a with 1-bromo-4-iodobenzene. The reactions all 
showed large quantities of the nBuLi reacting with itself or forming structures like 
butylbenzene. This reaction is an interesting route to creating derivatives of the target 
compound, and substitution at the 4 position of the piperidine backbone is very desirable. 
This reaction could increase the variety of substituents that can be installed and reduce 
costs by allowing the desired structures to be generated from simpler starting materials. 
Future development of the lithium-halogen exchange could involve controlling the rate of 
addition of the n-BuLi to the aryl halide starting material and controlling the time of 
addition of the ketone. The role of the concentration of the reactants could also be 
investigated. 
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Amine Alkylations of 4-Piperidinols 
 The second part of the strategy for modification of the lead compound involved 
modification at the 1 position of the piperidine backbone. The method used in both the 
alkylation-first and alkylation-second approach is an amine alkylation, an SN2 type 
reaction where the amine of the piperidinol acts as a nucleophile with an alkyl halide. The 
reaction, specifically from the alkylation-second approach, is outlined in Scheme 6. 
 
R1 Cl
Na2CO3
CH3CN
N
H
OHR2
N
R1
OH
9a-d
3a-c
R2
1, 6a-k
R2 = 4-Br
R2 = 4-Cl
R2 = 3-CHF3
R2 = H
R
1
1:
6a:
R16b:
R16c:
R16d:
R16e:
R1 = pyrenyl  R2 = 4-Br
R1 = naphthyl R2 = 4-Br
R1 = phenyl R2 = 4-Br
R1 = phenyl R2 = 4-Cl
R1 = naphthyl R2 = 4-Cl
R1 = pyrenyl R2 = 4-Cl
R16f:
R16g:
R16h:
R16i:
R16j:
R16k:
R1 = phenyl R2 = 3-CHF3
R1 = naphthyl R2 = 4-CHF3
R1 = pyrenyl R2 = 4-CHF3
R1 = phenyl R2 = H
R1 = naphthyl R2 = H
R1 = pyrenyl R2 = H
R
13
3a:
R13b:
R1443c:
R1 = phenyl
R1 = naphthyl
R1 = pyrenyl
 
Scheme 6: The amine alkylation reaction. 
 
 To save time and cost, this reaction used commercially available 9a-d starting 
material and aryl halides 3a-c to create 12 derivatives, 1, 6a-k. The reactants were 
refluxed with sodium carbonate in acetonitrile for at least one hour before gravity 
filtration and evaporation of the solvent. GCMS monitoring of the reaction showed the 
reaction generally completed within two hours. The reaction appeared to not have 
significant side reactions. Chromatograms of successful reactions showed only starting 
material and the desired product. Additionally, the reaction did not appear to generate the 
quaternary amine product, shown in Figure 10. 
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R2 = 4-Br
R2 = 4-Cl
R2 = 3-CHF3
R2 = H
R1 = phenyl
R1 = naphthyl
R1 = pyrenylalkylation
N
R1
OHR2
N
+
R1
OH
R1
R2
 
 
Figure 10: During amine alkylation, a quaternary ammonium cation can be formed. This 
unwanted product was not observed. 
 
 A likely reason that this reaction did not proceed to the quaternary ammonium 
cation is the steric bulk of the aryl halide R2 groups. Despite being similarly basic to its 
secondary amine counterpart, the tertiary amine does not participate in a second SN2 
reaction with the aryl chloride substrate, which is well supported by the literature in 
which alkylation of a piperidine to a tertiary benzylic amine is often shown with high 
yields under similar reaction conditions.20,21  
OH Cl
SOCl2
CH2Cl2, 0°C
3c
13
M
+
: 250
M
+
: 216
 
 
Figure 11: The synthesis of 3c and the unintended product 13. 
 
Unfortunately, the pyrenyl derivatives 1, 6e, 6h and 6k were not successfully 
synthesized. GCMS of 3c showed that the reaction used to generate this starting material 
19 
 
may have generated 13 instead of the aryl chloride, as shown in Figure 11. The mass 
spectra of the pyrene starting material is shown in Figure 12. The molecular ion mass 
(M+) is 216, which is identical to the molecular mass of 1-methylpyrene. The expected 
(1-chloromethyl)pyrene should have had a M+ of 250. Before this starting reagent had 
been characterized by GCMS, various pyrene alkylations were attempted, but none 
successfully generated the desired product. 
 
 
Figure 12: Mass spectrum of 13. This product was the result of an unsuccessful attempt 
to synthesize 3c. 
 
The products were all purified by column chromatography, typically in 
hexanes/ethyl acetate. TLC of most compounds on silica gave good relative migration 
(Rf) separation between the product and the nearest impurities, though streaking of the 
amine was common. Identifying the chromatography fractions by TLC was made more 
difficult by the resolution of identical compounds (as determined by GCMS) at different 
Rf. This may have been due to the presence of stereoisomers of the compound, however 
pyramidal inversion of nitrogen should prevent the resolution of these isomers, as the R/S 
configuration of amines rapidly interconverts at room temperature by a quantum 
tunneling mechanism. However, intramolecular hydrogen bonding has been shown to 
slow this interconversion significantly.22 A boat conformation of the piperidine backbone 
could create such a favorable interaction between the lone pair electrons of the amine and 
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the hydrogen of the hydroxy group, shown in Figure 13. This would generate a less flat 
structure than the chair conformation where both bulky aryl groups are equatorial. This 
curved structure would have a higher Rf due to fewer van der Waals interactions between 
the structure and the TLC substrate. Though this would be an interesting property to 
investigate further, the significance of this to synthesis is largely that higher yields were 
possible by using GCMS to identify fractions instead of TLC.  
N
O
H :
 
Figure 13: A boat conformation of 6i. The interaction between the lone pair of the amine 
and the hydrogen of the hydroxy group may result in intramolecular hydrogen bonding 
and a slower inversion of the amine. 
 
The yields of the amine alkylation reaction are summarized in Figure 14. 
Generally, the smaller aryl halide electrophiles had higher yields than their bulkier 
counterparts, with one exception of 4-(4-chloro)phenyl-1-naphthylmethyl-4-piperidinol 
(6). Overall this reaction is effective in derivatizing the lead compound in the 1 position. 
Future derivatives can be created based on this alkylation reaction. 
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R2
N
R1
OH
R2 = 4-Br
R2 = 4-Cl
R2 = 3-CHF3
R2 = H
R1 = benzyl
R1 = naphthyl
R1 = pyrenyl
 
R2 R1 benzyl naphthyl pyrenyl 
H 57  52 - 
4-Br 64 58 - 
4-Cl 63 85 - 
3-CHF3 77 TBD - 
Figure 14: The percent yields of each alkylation reaction after purification by flash 
chromatography. 
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Organosilane Reduction of Hydroxy Group 
N
R1
OH
Et3SiH, TFA
CH2Cl2
1, 6a-k
N
R1
14a-l
R2
R2
R
1
1:
6a:
R16b:
R16c:
R16d:
R16e:
R1 = pyrenyl  R2 = 4-Br
R1 = naphthyl R2 = 4-Br
R1 = phenyl R2 = 4-Br
R1 = phenyl R2 = 4-Cl
R1 = naphthyl R2 = 4-Cl
R1 = pyrenyl R2 = 4-Cl
R16f:
R16g:
R16h:
R16i:
R16j:
R16k:
R1 = phenyl R2 = 3-CHF3
R1 = naphthyl R2 = 4-CHF3
R1 = pyrenyl R2 = 4-CHF3
R1 = phenyl  R2 = H
R1 = naphthyl R2 = H
R1 = pyrenyl R2 = H  
Scheme 6: The overall reaction for the triethylsilane reduction of the hydroxy group. 
 
Following the creation of 1, 6a-k, reduction of the hydoxy group at position 4 was 
also attempted to generate 14a-l. The approach (Scheme 6) used silane reduction.23 
Triethylsilane in trifluoroacetic acid was used to remove the hydroxy group. One 
equivalent of 1, 6a-k was added to triethyl silane (9.5 equivalents) and trifluoroacetic 
acid (6.5 equivalents) and stirred overnight. Workup of the mixture was performed with 
sodium hydroxide, followed by purification via column chromatography. Initially, the 
reduction of 6 appeared to have been successful. Product formation was checked both by 
TLC and GCMS. In TLC, a higher Rf spot was generated relative to the starting material, 
which is expected for the less polar product on silica backed plates. However, mass 
spectrometry of the starting material and the product showed M+ of 199 and 217. The 
mass spectra of the two largest peaks on the mass chromatogram of the first attempt at 
reducing 6i are shown in Figure 15. 
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Figure 15: The mass spectra of two unexpected products of the silane reduction of 8. The 
circled peaks and their M+1 and M+2 peaks suggest that a silicon atom may be present in 
the molecule. Additional structural information may be possible with NMR analysis. 
 
 One of the products of the first reaction of 6i appeared to include silicon 
(indicated by the presence of M-28 peaks and the relatively large M+1 and M+2 peaks) 
which would have come from the triethylsilane. Silane reduction of alcohols is thought to 
proceed by the mechanism shown in Figure 16.24,25 The reaction requires dry conditions 
to avoid the formation of silanols.  
N
OHR
1
R
2
O
O
F
F
F
H
N
O
+
R
1
R
2
H
H
C
+
N
R
1
R
2
SiH
N
R
1
R
2
 
Figure 16: One proposed mechanism for the silane reduction, which proceeds through a 
carbocation intermediate. 
 
A second attempt at this reduction, this time using 6j, appeared to have a 12% 
yield. The mass spectrum of this product is shown in Figure 17. The M+ of the product is 
two amu less than expected. The reaction mixture had dried during stirring, so addition of 
a small amount of dichloromethane solvent was used in the proceeding reactions in an 
attempt to improve the yield. 
6i 
24 
 
 
 
 
Figure 17: A mass spectrum of the product of the reduction of 6j. The M+ peak at 299 is 
two less than the expected mass, 301. 
 
The first attempted reaction using dichloromethane solvent with 6i was 
unsuccessful, with only traces of possible product. This can potentially be attributed to 
the use of wet dichloromethane. The reaction was repeated with dry dichloromethane, 
and although it was not purified to find the yield, GCMS of the products suggest that the 
desired product may have been formed. A comparison of the two largest peaks in the 
chromatogram for the reaction of 6i in dry dichloromethane is shown in Figure 18. The 
two molecular ions are 249 and 267, with the lower M+ corresponding to the reduced 
compound. GCMS of the starting material, 6i, also has an M+ of 267, with an identical 
fragmentation pattern to the other abundant peak in the chromatogram of the reduction 
product mixture, demonstrating that unreacted starting material remained.  
 
 
6j 
background impurity M+ 
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Figure 18: The mass spectra of the two products of the reaction of 6i in dry acetonitrile. 
The fragmentation pattern shown in the top spectrum is identical to that of the starting 
material. The difference of 18 between the two spectra could be attributed to the loss of 
the hydroxy group. 
 
Interestingly, the product of the reduction of both 6i and 6j resulted in products 
whose m/z was smaller than expected by two AMU. This lower molecular ion mass may 
indicate that an elimination reaction is occurring, which is creating an alkene between the 
3 and 4 carbons of the piperidine ring, as shown in Figure 19. This alkene would create a 
flat region on the molecule that may greatly reduce the effectiveness of this structure as 
an inhibitor of KasA. 
N
MW: 299
N
MW: 249
 
Figure 18: The possible products of the reduction of 7 and 6, respectively. The potential 
unintended alkene locations are shown circled in red. The molecular masses of these two 
compounds corresponds better to the mass spectra than the alkane products. 
 
Overall this reaction requires additional optimization. Dry solvent and glassware 
are critical. Low yields compared to literature (67% reported with a similar structure) 
15 16 
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may be due to properties of the starting piperidinol, but the triethylsilane used may also 
have degraded.23 Investigation into the structures formed in Figure 15 may give insight 
into how to further improve the reaction conditions and avoid unwanted side reactions. 
Importantly, the reaction must be controlled to avoid the elimination product so that the 
typical geometry of the piperidine ring can remain. 
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III. Future Work 
For future work, in order to create a diverse collection of compounds for testing, 
several approaches are proposed, each with the aim of modifying either the 1 or 4 
position of the central piperidine ring in the lead compound. There are three new 
approaches for modification of the 1 position. First, a Grignard reaction will be 
attempted, using different functionalized iodo-aryl compounds and isopropyl magnesium 
chloride, as in Scheme 4. This scheme has been shown to be more effective at creating 
aryl Grignard reagents than a traditional Grignard reaction.17 
O
R1
I
Mg
Cl
O
R1
Mg
I
+
O
R2
R1
O
OH
N
R2 
Scheme 7: Grignard with isopropyl magnesium  chloride. 
 
The starting aryl chloride can be purchased or created by starting with 4-
iodophenol and performing a Williamson ether reaction to replace the hydroxide group 
with different alkoxy groups, as shown in Scheme 5.26,27 Adding alkyl chains to the 
compound may aid in enzyme inhibition because they mimic the fatty acid chains present 
in mycolic acid synthesis.12 
O
R
IR Br
DMF
O
H
I
 
Scheme 8: Williamson ether reaction. 
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The second approach to modifying the 4-position is a copper-catalyzed azide-
alkyne cycloaddition (CuAAC), or “click” reaction, which would replace the benzyl 
chloride of compound one with a functionalized triazole, as in Scheme 6. 
 
N
O
R1
Mg
Cl
N
OH
R1
R2
N
N
N
N
OH
N
NN
R2
R1
CuSO4
Sodium Ascorbate
H2O, tBuOH
 
 
Scheme 9: Cu(I)-catalyzed azide-alkyne cycloaddition. 
 
Importantly, 1-chloromethylpyrene must be synthesized to create critical pyrenyl 
derivatives via amine alkylation. The 1-chloromethylpyrene synthesis used is shown in 
scheme 10.28 This reaction was unsuccessful in previous work, but this reaction should be 
robust. Additional attempts should result in synthesis of the desired compound. 
 
OH Cl
SOCl2
CH2Cl2, 0°C
 
Scheme 10: The synthesis of (1-chloromethyl)pyrene. 
 
In the long-term, the library of derivatives of the lead compound will be tested for 
affinity to KasA, and their effects on nonpathogenic mycobacteria will be observed. 
These compounds may aid in the continuing search for potent inhibitors that can aid in 
halting MDR-TB. 
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IV. Experimental 
Suppliers and purities of all chemicals are listed in Appendix I. All reagents were used as 
received unless noted. Column chromatography was conducted on a Biotage Isolera One 
flash system. Gas Chromatography Mass Spectrometry was performed with a Shimadzu 
GCMS-QP5050A Gas Chromatograph/Mass Spectrometer. Anhydrous tetrahydrofuran 
(THF) and dichloromethane were dispensed from an MBraun Solvent Purification 
System. 
1-Benzyl-4-(4-bromophenyl)-4-piperidinol (6b). In a 50 mL round bottomed flask with 
magnetic stir bar and condenser, 268 mg (1.04 mmol, 1.01 eq) of 4-(4-bromophenyl)-4-
piperidinol, 131 mg (1.03 mmol, 1.00 eq) of benzyl chloride, and 326 mg (3.07 mmol, 
2.98 eq) sodium carbonate were added. Acetontrile (10 mL) was added as solvent. The 
mixture was refluxed for 16 hours, and the crude mixture was monitored by TLC (50% 
hexanes in ethyl acetate, product Rf = 0.29), showing product formation. The reaction 
mixture was gravity filtered and the solids were washed with an additional 20 mL of 
acetonitrile. The solvent was then removed under vacuum. The product was purified by 
flash chromatography (SNAP Ultra 10g column, dichloromethane/methanol gradient). 
Crude yield: 95%; purified yield: 62%. MS m/z: [M+] calcd 346; found 346 
1-Benzyl-4-(4-chlorophenyl) -4-piperidinol (6c). In a 50 mL round bottomed flask with 
a magnetic stir bar and condenser, 317 mg (2.99 mmol, 2.93 eq) sodium carbonate, 225 
mg (1.06 mmol, 1.03 eq) 4-(4-chlorophenyl)-4-piperidinol, and 137 mg (1.02 mmol, 1.00 
eq) of benzyl chloride was refluxed in 10 mL of acetonitrile for 16 hours. The reaction 
mixture was monitored by TLC (9% methanol in dichloromethane, product Rf = 0.30) 
and gravity filtered. The waste solids were washed with 20 mL of acetonitrile, and 
30 
 
solvent removed under vacuum. The crude product was purified by flash chromatography 
(SNAP Ultra 10g column, dichloromethane/methanol gradient). Crude yield: 99%, 
purified yield: 63%. MS m/z: [M+] calcd 301; found 301 
4-(4-Chlorophenyl)-1-(1-naphthylmethyl)-4-piperidinol (6d). In a 50 mL round 
bottomed flask with stir bar and condenser, 319 mg (3.01 mmol, 3.01 eq) sodium 
carbonate, 224 mg (1.06 mmol, 1.06 eq) 4-(4-chlorophenyl)-4-piperidinol, and 177 mg 
(1.00 mmol, 1.00 eq) 1-(chloromethyl)naphthalene were refluxed in 10 mL of acetonitrile 
for 19 hours, at which time the reaction mixture was monitored by TLC (9% methanol in 
dichloromethane, product Rf = 0.48) and gravity filtered. The waste solids were washed 
with 20 mL of acetonitrile and the solvent removed under vacuum. The product was 
purified by flash chromatography (SNAP Ultra 10g column, dichloromethane/methanol 
gradient). Crude yield: 99%, purified yield: 85%. MS m/z: [M+] calcd 351; found 351 
1-Benzyl 4-[3-(trifluoromethyl)phenyl]-4-piperidinol (6f). In a 100 mL round 
bottomed flask with magnetic stir bar and condenser, 270 mg (2.13 mmol, 1.01 eq) 
benzyl chloride, 517 mg (2.11 mmol, 1.00 eq) 4-[3-(trifluoromethyl)phenyl]-4-
piperidinol, and 639 mg (6.02 mmol, 2.85 eq) sodium carbonate were refluxed in 20 mL 
acetonitrile for 24 hours. The reaction was monitored by GCMS (m/z 335) showing 
product formation during the first hour of the reaction. TLC confirmed product formation 
(50% hexanes in ethyl acetate, product Rf = 0.31). The mixture was gravity filtered and 
the solid waste was washed with 20 mL acetonitrile. The solvent was removed under 
vacuum. Automated flash chromatography (10 g SNAP Ultra, hexanes/ethyl acetate 
gradient) was used for purification. Crude yield: 88%, purified yield: 73%. MS m/z: [M+] 
calcd 335.36; found 335.10 
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1-Benzyl-4-phenyl-4-piperidinol (6i). In a 50 mL round bottomed flask with magnetic 
stir bar and condenser, 341 mg (3.22 mmol, 2.98 eq) sodium carbonate, 192 mg (1.08 
mmol, 1.00 eq) 4-hydroxy-4-phenylpiperidine, and 131 mg (1.03 mmol, 0.95 eq) benzyl 
chloride were refluxed in 10 mL acetonitrile for 20 hours and then monitored by TLC 
(50% hexanes in ethyl acetate, product Rf = 0.25). The mixture was gravity filtered and 
the waste solids were washed with 20 mL acetonitrile. The solvent was removed under 
vacuum, and the product was purified by automated flash chromatography (10 g SNAP 
Ultra column, hexanes/ethyl acetate gradient). Crude yield: 94%, purified yield: 57%. MS 
m/z: [M+] calcd 267; found 267 
1-(1-Naphthylmethyl)-4-phenyl-4-piperidinol (6j). In a 100 mL round bottomed flask 
with stir bar and condenser, 372 mg (2.11 mmol, 1.00 eq) 1-(chloromethyl)naphthalene, 
381 mg (2.15 mmol, 1.02 eq) 4-hydroxy-4-phenylpiperidine, and 641 mg (6.04 mmol, 
2.86 eq) sodium carbonate was refluxed in 20 mL acetonitrile for 18 hours. The reaction 
was then monitored by TLC (50% hexanes in ethyl acetate, product Rf = 0.48) and 
gravity filtered. The waste solids were washed with 20 mL acetonitrile and the solvent 
was removed under vacuum. Automated flash chromatography (10 g SNAP Ultra 
column, hexane/ethyl acetate gradient) was used to purify the product. Crude yield: 99%, 
purified yield: 52%. MS m/z: [M+] calcd 317.42; found 317.25 
1-Boc-4-phenyl-4-piperidinol (8d). In a dry round bottomed flask with Claisen adapter, 
condensing tube and addition funnel, 245 mg (10.1 mmol,1.00 eq) magnesium turnings 
were placed in 3 mL dry THF. The vessel was heated to 70 °C. Dropwise through the 
addition funnel, 1.63 g bromobenzene (10.4 mmol, 1.03 eq), was added in 4 mL of 
additional dry THF. After 30 minutes of stirring, the reaction was cooled and 2.003 g 
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(10.1 mmol, 1.00 eq) boc-piperidone dissolved in 3 mL THF was added through the 
addition funnel dropwise. The reaction was heated again for 15 minutes, then cooled. The 
product mixture was quenched with 8 mL H2O and 1 mL of 1M ammonium chloride. It 
was then extracted with 3x20 mL ethyl acetate and dried over magnesium sulfate. The 
crude product was gravity filtered and characterized by GCMS. Crude yield: 75% MS 
m/z: [M+] calcd 277; found 277 
1-Methylpyrene (13). In a 250 mL round bottomed flask with magnetic stir bar and a 
drying tube, 2.13 g (9.18 mmol, 1.00 eq) of 1-pyrenemethanol and 1.6 mL (22 mmol, 2.4 
eq) of thionyl chloride was dissolved in 50.5 mL of dichloromethane and stirred at room 
temperature. A TLC after one hour showed a partial reaction (80% hexane in ethyl 
acetate; product Rf = 0.5). After 19 hours, TLC (50% hexanes in ethyl acetate; product Rf 
= 0.78) showed some starting material remaining. The solvent was removed under a 
vacuum, leaving a green flaky solid. The product was used without further purification. 
MS m/z: [M+] calcd 216; found 216  
1,2,3,6-Tetrahydro-1-(1-napthylmethyl)-4-phenylpyridine (15). In a dry 50 mL round 
bottomed flask with magnetic stir bar and septa, 330 mg (1.03 mmol, 1.03 eq) of 
compound 7, 1.1 mL of triethylsilane (9.5 mmol, 9.5 eq), and 0.5 mL (6.5 mmol, 6.5 eq) 
of trifluoroacetic acid were stirred under nitrogen atmosphere for 24 hours. The reaction 
was diluted with 30 mL dichloromethane, washed with 3x20 mL 1M sodium hydroxide, 
and dried over magnesium sulfate. A TLC plate was developed with the reaction mixture 
(50% hexanes in ethyl acetate, product Rf = 0.69). Automated flash chromatography was 
used for purification, giving white crystals. Crude yield: 23%, purified yield, 16%. MS 
m/z: [M+] calcd 299; found 299 
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1-Benzyl-1,2,3,6-tetrahydro-4-phenylpyridine (16). In a dry 25 mL round bottomed 
flask with magnetic stir bar and septum, 140 mg (0.52 mmol, 0.52 eq) compound 6, 0.5 
mL (4.3 mmol, 4.3 eq) triethylsilane, and 0.25 mL (3.25 mmol, 3.25 eq) trifluoroacetic 
acid were stirred at room temperature under nitrogen for 24 hours. The mixture was 
diluted in 15 mL dichloromethane, washed with 2x30 mL of 1 M sodium hydroxide, and 
dried over magnesium sulfate. The solvent was removed under vacuum, and a TLC of the 
mixture was developed (50% hexanes in ethyl acetate, product Rf = 0.55). Automated 
flash chromatography (10 g SNAP Ultra column, hexanes/ethyl acetate gradient) was 
used for purification, giving yellow-white crystals. MS m/z: [M+] calcd 249; found 249 
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Appendix I 
Materials 
Reagents and Materials Provider Purity 
1-Pyrenemethanol TCI AMERICA 98.00% 
Thionyl chloride, Reagentplus Sigma Aldrich Corporation 99.50% 
Hexane Thermo Fisher Scientific Pesticide Residue 
Analysis Grade 
Ethyl acetate Thermo Fisher Scientific HPLC Grade 
TLC plates, silica gel on glass Aldrich - 
1,4-Dibromobenzene Thermo Fisher Scientific 99% 
n-Butyllithium, 2.2 M in hexane Alfa Aesar - 
1-Benzyl-4-piperidone Alfa Aesar 98% 
Tetrahydrofuran Thermo Fisher Scientific Laboratory Grade 
Ammonium chloride Sigma Aldrich Corporation 99.50% 
Magnesium sulfate, anhydrous Thermo Fisher Scientific Certified Powder 
Diphenylacetic acid Alfa Aesar recrystallized 
Cyclohexanone Thermo Fisher Scientific 98% 
Ethyl ether Thermo Fisher Scientific Laboratory Grade 
Nitrogen, compressed gas Airgas, Inc. - 
Chloroform Sigma Aldrich Corporation 99% 
Iodine Sigma Aldrich Corporation Certified ACS 
1-Bromo-4-iodobenzene Thermo Fisher Scientific 98% 
1-Boc-4-piperidone Alfa Aesar 99% 
4-(4-Bromophenyl)-4-piperidinol Sigma Aldrich Corporation 98% 
Benzyl chloride Thermo Fisher Scientific 99.5% 
Sodium carbonate, anhydrous Sigma Aldrich Corporation 99% 
Acetonitrile, anhydrous Thermo Fisher Scientific 99.90% 
1-(Chloromethyl)naphthalene Thermo Fisher Scientific 95% 
4-(4-chlorophenyl)piperidin-4-ol ChemBridge Corporation 95% 
Magnesium turnings Alfa Aesar 99.80% 
4-Hydroxy-4-phenylpiperidine TCI AMERICA 98% 
4-[3-(Trifluoromethyl)phenyl]-4-
piperidinol 
Alfa Aesar 97% 
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Appendix II 
Spectra 
(1) 1-methylpyrene 
MW: 216.28, m/z [M+]: 216 
 
(2) 1-boc-4-phenyl-4-piperidinol 
MW: 277.36, m/z [M+]: 277 
m/z 341, 355 due to siloxane background impurity (column bleed)29 
 
 
 
 
 
 
 
 
 
background impurity [M+] 
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(3) 1-benzyl-4-(4-bromophenyl)-4-piperidinol  
MW: 346.26, m/z [M+]: 345.10 
m/z 345.10 one less than MW due to loss of H from OH group 
m/z 347.10 [M+2] isotope peak from Br 
 
 
(4) 1-benzyl-4-(4-chlorophenyl)-4-piperidinol  
MW: 301.81; m/z [M+]: 301.20 
 
(5) 4-(4-chlorophenyl)-1-(1-naphthylmethyl)-4-piperidinol  
MW: 351.87; m/z [M+]: 351.15 
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(6) 1-benzyl-4-phenyl-4-piperidinol 
MW: 267.37; m/z [M+]: 267.20 
m/z 281 due to siloxane background impurity (column bleed)29 
 
 
 
 
(7) 1-(1-naphthylmethyl)-4-phenyl-4-piperidinol 
MW: 317.42; m/z [M+]: 317.25 
m/z 343, 355 due to background impurity29 
 
 
 
 
(8) 1-benzyl 4-[3-(trifluoromethyl)phenyl]-4-piperidinol  
MW: 335.36; m/z [M+]: 335.10 
 
background impurity [M+] 
[M+] background impurities 
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(9) 1-benzyl-1,2,3,6-tetrahydro-4-phenylpyridine  
MW: 249.35; m/z [M+]: 249 
 
  
(10) 1,2,3,6-tetrahydro-1-(1-napthylmethyl)-4-phenylpyridine  
MW: 299.41; m/z [M+]: 299 
 
 
 
 
